Research programme: pain therapeutics - Interprotein Corporation/RaQualia Pharma

Drug Profile

Research programme: pain therapeutics - Interprotein Corporation/RaQualia Pharma

Alternative Names: PPI inhibitors - Interprotein/RaQualia Pharma; Protein-protein interaction inhibitors - Interprotein/RaQualia Pharma

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Interprotein Corporation; RaQualia Pharma
  • Class Small molecules
  • Mechanism of Action Protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Pain

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for research development in Pain in Japan
  • 01 Feb 2013 Early research in Pain in Japan (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top